Showing 3111-3120 of 4166 results for "".
- Acuity Eyecare Group Announces Rebranding and New Corporate Namehttps://modernod.com/news/acuity-eyecare-group-announces-rebranding-and-new-corporate-name/2477131/Acuity Eyecare Group, which operates leading eyecare groups across the U.S. and has backing by private equity group Riata Capital, is announcing a new name, AEG Vision, along with other corporate updates, according to a
- Solving a Medical Mystery Crucial to Future Space Travelhttps://modernod.com/news/solving-a-medical-mystery-crucial-to-future-space-travel/2477089/Astronauts often wrestle with blurry vision during spaceflight and this problem is jeopardizing longer missions to Mars, according to a report in Medscape. Half of the astronauts on the International Space Station have already expe
- Eyenovia Advances MicroLine for the Treatment of Presbyopia; Reprioritizes Late-Stage Ophthalmology Pipelinehttps://modernod.com/news/eyenovia-advances-microline-for-the-treatment-of-presbyopia-reprioritizes-late-stage-ophthalmology-pipeline/2477052/Eyenovia announced that the company is advancing the development of its MicroLine program for the improvement in near vision in patients with presbyopia toward phase 3 development. As a result of prioritizing MicroLine in tandem with its MicroPine (progressive myopia) and MicroSta
- Oculus Teams Up With BHVI to Improve Myopia Managementhttps://modernod.com/news/oculus-teams-up-with-bhvi-to-improve-myopia-management/2477036/Oculus and BHVI (Brien Holden Vision Institute) have announced an agreement that will allow Oculus to incorporate BHVI’s algorithms for tracking and estimating refractive error into its Myopia Master ophthalmic instruments developed for the management of myopia.
- EyeCarePro Acquires the Optometrists Networkhttps://modernod.com/news/eyecarepro-acquires-the-optometrists-network/2476917/As part of an overall business strategy of expanding services for optometric medical specializations, EyeCarePro acquired the assets belonging to the Optometrists Network in July 2019, according to a report in VisionMonday. These include the related networks of vision therapy and neuro-opt
- CooperVision Seeks Submissions for 2020 Best Practices Honoreeshttps://modernod.com/news/coopervision-seeks-submissions-for-2020-best-practices-honorees/2476909/Among thousands of eye care professionals at Vision Expo West in Las Vegas, CooperVision announced today its fifth annual search for the nation’s 2020 Best Practices (
- Bausch + Lomb Ultra Multifocal for Astigmatism Contact Lenses Now Available In the United Stateshttps://modernod.com/news/bausch-lomb-ultra-multifocal-for-astigmatism-contact-lenses-now-available-in-the-united-states/2476671/Bausch + Lomb announced the US launch of Bausch + Lomb Ultra Multifocal for Astigmatism contact lenses. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision n
- Key to Workplace Productivity May Be in the Eyeshttps://modernod.com/news/key-to-workplace-productivity-may-be-in-the-eyes/2476606/While employers are constantly striving to enhance worker productivity, a new study from the journal Ophthalmology suggests a solution: correcting nearsightedness. Conducted by global researchers, the study indicates that vision impairment caused by uncorrected myopia cost the globa
- Wills Eye Hospital Research Suggests Glaucoma Patients May Be at Higher Risk of Motor Vehicle Accidents Than Those of Similar Agehttps://modernod.com/news/wills-eye-hospital-research-suggests-glaucoma-patients-may-be-at-higher-risk-of-motor-vehicle-accidents-than-those-of-similar-age/2476601/In a study recently presented at The Association for Research in Vision and Ophthalmology (ARVO), researchers from Wills Eye Hospital in Philadelphia studied the rate of car accidents in patients with glaucoma. They found that the rate of those accidents among pat
- Nicox Presents First Data on New Class of Nitric Oxide (NO)-Donating Compounds for Glaucoma at ARVOhttps://modernod.com/news/nicox-presents-first-data-on-new-class-of-nitric-oxide-no-donating-compounds-for-glaucoma-at-arvo/2476545/Nicox SA announced that it has presented the first data from a new drug class designed to lower IOP (NO-donating PDE5 inhibitors) at a poster presentation during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The first